[go: up one dir, main page]

GB1137379A - Pharmaceutical preparation - Google Patents

Pharmaceutical preparation

Info

Publication number
GB1137379A
GB1137379A GB4880967A GB4880967A GB1137379A GB 1137379 A GB1137379 A GB 1137379A GB 4880967 A GB4880967 A GB 4880967A GB 4880967 A GB4880967 A GB 4880967A GB 1137379 A GB1137379 A GB 1137379A
Authority
GB
United Kingdom
Prior art keywords
parts
mixture
tablet
hydrochloride
drying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4880967A
Inventor
Sampson Frederic Jeffries
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Chemical Co
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Priority to GB4880967A priority Critical patent/GB1137379A/en
Publication of GB1137379A publication Critical patent/GB1137379A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1,137,379. Sustained release tablets; multilayer tablets. DOW CHEMICAL CO. 26 Oct., 1967, No. 48809/67. Heading A5B. A method of preparing a pharmaceutical preparation in the form of a slowly disintegrable tablet comprises intimately admixing, by weight, 25-47 parts of an active major ingredient with 4-6 parts of an ethyl cellulose; wetting the admixture with alcohol and then drying to remove alcohol; intimately admixing the so-dried admixture with a wet granulation consisting of 0-20 parts total of one or more therapeutic substances, 3-8 parts tragacanth, 16-24 parts glyceryl monostearate, 16-24 parts karaya gum and water; drying and sieving the mixture; coating the sieved mixture with an alcoholic solution of an ethyl cellulose containing 1.3-2 parts of an ethyl cellulose; drying the coated mixture to remove alcohol 'therefrom; sieving the dried mixture and blending with a running powder containing talc and magnesium stearate and compressing into tablet form: The compressed tablet may be presscoated or made part of a multilayer tablet, the press-coat or additional layer being generally made up of one or more physiologically active materials selected from the active major ingredient or smaller proportion therapeutic substance together with a readily soluble or dispersible physiologically inert carrier such as milk sugar, in addition to starch powder and lubricants such as talc and magnesium stearate. In the case of the multilayer tablet, at least some surface area of the prior formed tablet is exposed in the multilayer tablet. Suitable major ingredients include aspirin, phydroxy acetanilide or mixture thereof; a mixture of aspirin, acetophenetidin and caffeine; salicylates e.g. sodium, potassium, ammonium or calcium salicylate; salicylamide; inorganic bromides e.g. sodium, potassium ammonium, calcium or magnesium bromide; ascorbic acid and physiologically compatible mixtures thereof. Smaller proportion therapeutic agents include a salicylate, aspirin, p-hydroxy-acetanilide, phenylpropanolamine hydrochloride, pseudoepinephrine hydrochloride, cyclopentamine hydrochloride, phenylephrine hydrochloride, pyrilamine, phenyltolxamine citrate, prophenpyridamine maleate, chlorpheniramine maleate, belladonna alkaloids, synthetic antichlolinergics, vitamins and growth factors.
GB4880967A 1967-10-26 1967-10-26 Pharmaceutical preparation Expired GB1137379A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB4880967A GB1137379A (en) 1967-10-26 1967-10-26 Pharmaceutical preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB4880967A GB1137379A (en) 1967-10-26 1967-10-26 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
GB1137379A true GB1137379A (en) 1968-12-18

Family

ID=10449979

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4880967A Expired GB1137379A (en) 1967-10-26 1967-10-26 Pharmaceutical preparation

Country Status (1)

Country Link
GB (1) GB1137379A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0235986A1 (en) * 1986-02-13 1987-09-09 Ethical Pharmaceuticals Limited Slow release formulation
US5879714A (en) * 1996-04-24 1999-03-09 Bernard Charles Sherman Controlled-release pharmaceutical compositions

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0235986A1 (en) * 1986-02-13 1987-09-09 Ethical Pharmaceuticals Limited Slow release formulation
JPS62215519A (en) * 1986-02-13 1987-09-22 エチカル・フアーマシユーテイカルズ・リミテツド sustained release composition
US4880830A (en) * 1986-02-13 1989-11-14 Ethical Pharmaceuticals Limited Slow release formulation
JPH0655669B2 (en) * 1986-02-13 1994-07-27 エチカル・フアーマシユーテイカルズ・リミテツド Sustained release composition
US5879714A (en) * 1996-04-24 1999-03-09 Bernard Charles Sherman Controlled-release pharmaceutical compositions

Similar Documents

Publication Publication Date Title
US4309405A (en) Sustained release pharmaceutical compositions
SU1709894A3 (en) Method for producing granules
US4259314A (en) Method and composition for the preparation of controlled long-acting pharmaceuticals
US4309406A (en) Sustained release pharmaceutical compositions
KR880002673B1 (en) Analgesic capsule
KR910014120A (en) Oral Pharmaceutical Formulations of Fimovevenan
CA1040532A (en) Process for producing solid bismuth-containing pharmaceutical compositions
ATE15599T1 (en) DELAYED RELEASE PHARMACEUTICAL PREPARATION.
RU2004131870A (en) PHARMACEUTICAL PRODUCT CONTAINING OXYCODONE AND NALOXONE
CA1071105A (en) Augmentation of blood levels of aspirin
US4859469A (en) Novel galenic forms of verapamil, their preparation and medicines containing said novel galenic forms
EA023532B1 (en) Floating microgranules
HU230033B1 (en) Composition containing n-acetyl-p-aminophenol
FI86373B (en) Coating for a pharmaceutical tablet with delayed action and a method for the production of a tablet
US4888343A (en) Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
KR0177493B1 (en) Process for the preparation of a tablet containing a heat light and moisture sensitive active ingredient having monoclinic crystal structure
ATE17650T1 (en) DRY POWDERED N-ACETYL-P-AMINOPHENOL COMPOSITIONS AND PROCESS FOR THEIR PREPARATION.
GB1279214A (en) Long-acting oral carrier
JPH0428685B2 (en)
RO112084B1 (en) Pharmaceutical composition which contains furane derivates and preparation process thereof
GB1137379A (en) Pharmaceutical preparation
DE3517820A1 (en) PHARMACEUTICAL PREPARATIONS WITH ANTI-HYPERTENSIVE AND CARDIOPROTECTIVE EFFECT
US3039922A (en) Method of administering tablets having decongestant and anti-histaminic activity
KR19990023194A (en) Silanesetron formulation stabilized against racemization reaction
GB630439A (en) Improvements in or relating to pharmaceutical preparations